Antibacterial Agents in Clinical Development

An analysis of the antibacterial clinical development pipeline, including tuberculosis

by Peter Beyer, Ursula Theuretzbacher, Simon Gottwalt et al.
World Health Organization, 2017

48 pp. 955 kB
http://apps.who.int/iris/bitstream/10665/258965/1/WHO-EMP-IAU-2017.11-eng.pdf?ua=1

The report shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance. Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250 000 people each year. In addition to multidrug-resistant tuberculosis, WHO has identified 12 classes of priority pathogens – some of them causing common infections such as pneumonia or urinary tract infections – that are increasingly resistant to existing antibiotics and urgently in need of new treatments.

(Visited 6 times, 1 visits today)
This entry was posted in Essential Medicines, General, Global Health, Other Infectious Diseases. Bookmark the permalink.